Stada says it is offering the first generic rival to Janssen’s Velcade (bortezomib) cancer treatment in 14 European countries, having developed an innovative ready-to-use solution as an alternative to the reference brand’s lyophilized powder for injection.
“The product launch of Bortezomib Stada is one of the most important international launches in Stada’s history and has clear...








